Eberprot-P

The newest drug Eberprot-P, developed by Cuban specialists using modern biotechnology, is successfully used as a therapy for ulcerative skin diseases in patients with diabetes. Just a few years ago, diabetic lesions of the lower extremities often led to their forced amputation.

This medication has been tested and refined for over two decades, and is only now being presented in world medicine as a unique and effective remedy of its kind.

The drug Eberprot-P is available in pharmacies with a prescription.

[ 1 ]

Indications Eberprot-P

Eberprot-P is used for therapeutic purposes in diabetic foot syndrome in patients with trophic and neuropathic ulcers of grades 3 and 4 (according to Wagner's classification), larger than 1 square centimeter in size, with a threat of limb amputation. Long-term non-healing ulcers, which are characterized by deep tissue damage, especially require the use of Eberprot-P.

[ 2 ]

Release form

Powdered substance for the preparation of a solution for injection in vials, 1 or 6 pieces per package.

Each vial contains 75 mcg of recombinant human epidermal growth factor and some excipients.

[ 3 ], [ 4 ]

Pharmacodynamics

The active substance of Eberprot-P is a protein that can stimulate cell growth and differentiate the epithelial cover using EGF. The protein consists of 53 amino acid residues and three intramolecular disulfide bonds.

The drug activates the migratory and proliferative properties of fibroblasts, keratinocytes and other cells, which promote ulcer healing, normal epithelial growth and tissue renewal.

The drug is of great importance for regulating metabolic and recovery processes in the body. By connecting with receptors on the surfaces of cell membranes, Eberprot-P activates anti-inflammatory processes, as well as differentiation of recovering cells, due to which the wound heals quickly and efficiently.

In addition, the drug controls the growth of epithelial, endothelial cells and fibroblasts, accelerates proliferative processes in tissues, and stabilizes the motor response of cells as a result of exposure to irritants.

[ 5 ]

Pharmacokinetics

There is no reliable scientific data on the chemical and biological processes that occur with the drug Eberprot-P in the body. The processes of biochemical transformation of the active substance molecules (absorption rate, degree of distribution, metabolism and elimination of Eberprot-P) have not yet been sufficiently studied.

Dosing and administration

Before using Eberprot-P, possible infectious lesions in the ulcerated areas should be treated.

If the benignity of a wound is in doubt, a tissue biopsy should be performed.

The drug is used as part of complex therapy for the disease. The standard dosage is 75 mcg, which is diluted in 5 ml of water for injection. It is used for injections of wounds or the periwound area, usually every other day. Treatment continues until positive epithelial proliferation, or until the wound is fully prepared for skin grafting surgery.

When injecting a wound, needles should be changed when changing injection sites of Eberprot-P to avoid possible spread of infection.

If a three-week period of continuous treatment has not improved the dynamics of the granulation process, the doctor should review the therapeutic measures and find the cause that may interfere with wound healing.

The medicinal substance from one vial can only be used by one and the same patient.

[ 8 ]

Use Eberprot-P during pregnancy

There is currently no data on the effect of Eberprot-P on the course of pregnancy and the developing embryo. The decision on the possibility of using Eberprot-P during pregnancy should be made by a doctor after assessing the clinical picture and the possible risk to the future baby.

Contraindications

Contraindications for the administration of Eberprot-P are:

• allergic sensitivity of the body to any of the components of the drug;
• the presence of benign and malignant tumors on the treated area of the skin;
• signs of diabetic coma and ketoacidosis, cardiopathy in the decompensation stage;
• pregnancy and breastfeeding;
• newborn children.

[ 6 ]

Side effects Eberprot-P

The main side effects when using Eberprot-P are considered to be:

• pain and numbness at the injection site;
• febrile conditions;
• a feeling of trembling in the limbs;
• development of local infection;
• feeling of heat.

[ 7 ]

Overdose

There have been no cases of drug overdose. There is no specific antidote.

In case of possible suspicion of drug overdose, symptomatic therapy is carried out.

Interactions with other drugs

Studies to determine the compatibility and interaction of Eberprot-P with other medications have not been conducted. Therefore, it is recommended to avoid the use of topical agents during treatment with the drug.

[ 9 ], [ 10 ]

Storage conditions

The drug should be stored in the original packaging in a refrigerator; it should not be frozen! The drug should be kept out of the reach of children.

[ 11 ]

Shelf life

The shelf life of Eberprot-P is 2 years. The diluted preparation is subject to immediate use. At the end of treatment, any unused product must be discarded.

[ 12 ], [ 13 ]